<?xml version="1.0" encoding="UTF-8"?>
<p>Serious adverse events (SAE) including deaths occur following administration of YF vaccine [
 <xref rid="B27-vaccines-07-00179" ref-type="bibr">27</xref>,
 <xref rid="B94-vaccines-07-00179" ref-type="bibr">94</xref>,
 <xref rid="B95-vaccines-07-00179" ref-type="bibr">95</xref>,
 <xref rid="B96-vaccines-07-00179" ref-type="bibr">96</xref>], and the frequency of vaccine-related SAEs for YF vaccine is comparable to the rate of vaccine-associated paralytic poliomyelitis with oral polio vaccine [
 <xref rid="B97-vaccines-07-00179" ref-type="bibr">97</xref>,
 <xref rid="B98-vaccines-07-00179" ref-type="bibr">98</xref>]. In addition, because YF vaccine is a live-attenuated vaccine produced in eggs, there are several contraindications and precautions to its administration [
 <xref rid="B99-vaccines-07-00179" ref-type="bibr">99</xref>]. Experts have called for the development of a safer YF vaccine ever since viscerotropic disease, an acute illness resembling severe wild-type disease but with higher lethality, was identified [
 <xref rid="B96-vaccines-07-00179" ref-type="bibr">96</xref>,
 <xref rid="B97-vaccines-07-00179" ref-type="bibr">97</xref>]. However, until we have a safer vaccine, healthcare providers and public health officials will have to determine if the benefit outweighs the risk among travelers to endemic areas and for populations living in non-endemic areas bordering endemic areas. 
</p>
